The Taiwan Pharmaceutical Manufacturers Association points out that foreign pharmaceuticals makers account for one-third of the market for medications in Taiwan, but take up 70 % of NHIB payments for meds. Not only does the NHIB pay excessively high prices for drugs which hospitals must purchase from the patent-holding manufacturers, even many products whose patents have expired continue to enjoy inappropriately high prices.
台灣區製藥公會進一步指出，外商藥廠的藥品佔全台用藥的三分之一，卻佔健保局藥品給付總價的七成，健保對原廠藥的給付價格不僅偏高，許多過了專利期的藥品，還繼續享有不當的高價。